News Releases

Date Title  
Toggle Summary Adamis’ Commercial Partner Launches SYMJEPI™ (epinephrine) in the US
SAN DIEGO , Jan. 16, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its marketing and commercial partner, Sandoz Inc. ( Sandoz ), a Novartis division, has launched SYMJEPI™ (epinephrine) 0.3 mg Injection in the US market for the emergency treatment
Adamis’ Commercial Partner Launches SYMJEPI™ (epinephrine) in the US
SAN DIEGO , Jan. 16, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its marketing and commercial partner, Sandoz Inc. ( Sandoz ), a Novartis division, has launched SYMJEPI™ (epinephrine) 0.3 mg Injection in the US market for the emergency treatment